Sequencing Nuances in MBC

CE / CME

Sequencing Nuances: Managing Complexities and Brain Metastases

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.50 Nursing contact hour

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: March 27, 2025

Expiration: September 26, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

When discussing treatment plans with colleagues and patients, how confident are you in summarizing the recommended sequencing of HER2-targeted therapies for HER2+ MBC treatment based on the latest data and clinical guidelines?

2.

Case: Mary with metastatic HR-/HER2+ BC



  • Mary, 57, is diagnosed with metastatic HR-/HER2+ breast cancer with 1 small liver lesion

  • 24 mo after THP treatment, she progresses on maintenance HP with disease progression in the liver and develops 1 brain lesion

  • She then received T-DXd and had a partial response, but 8 mo later she has developed new liver metastases and MRI shows 3 new brain lesions

After local therapy to the brain, which of these regimens would you recommend for Mary now?